Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HSF1 | Q00613 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10264625 | 0.83 | NPC1 (0.51) | LMNANPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL4508812 | 0.82 | SOS1 (0.45) | LMNANPC1RAB9ATP53KMT2A | |
| SCHEMBL3858092 | 0.82 | GRK6 (0.55) | NPC1RAB9ASMN1; SMN2KDM4EMAPT | |
| SCHEMBL2328520 | 0.82 | PIM1 (0.47) | NPC1RAB9ASMN1; SMN2KMT2AKDM4E | |
| SCHEMBL10203112 | 0.82 | SIGMAR1 (0.45) | LMNANPC1RAB9ASOS1 | |
| SCHEMBL24782964 | 0.79 | TP53 (0.45) | LMNANPC1RAB9ATP53KMT2A | |
| SCHEMBL14135144 | 0.79 | SOS1 (0.42) | LMNANPC1RAB9ATP53KMT2A | |
| SCHEMBL2320507 | 0.79 | SOS1 (0.42) | LMNANPC1RAB9ASOS1 | |
| SCHEMBL2322280 | 0.79 | SOS1 (0.40) | LMNANPC1RAB9ATP53SOS1 | |
| SCHEMBL22455584 | 0.79 | NPC1 (0.50) | LMNANPC1RAB9AKMT2ASOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074115-B1 | N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2018-03-07 | — | — | EP | disclosed |
| US-9650391-B2 | N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-9156820-B2 | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20140323490-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-8796259-B2 | N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8741898-B2 | Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130090330-A1 | N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323490-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB3 | LMNA 4178/4885NPC1 4043/4885RAB9A 2186/4885 |
| US-20130090330-A1 | N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB3 | LMNA 3877/4885NPC1 3825/4885RAB9A 2546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.